logo-loader
HealthPharma & Biotech
viewFaron Pharmaceuticals Ltd

Faron Pharma: Japanese data bears out earlier study result

Chief executive Dr Markku Jalkanen pointed out: “It appears likely that corticosteroid use diminished the treatment benefit of Traumakine in ARDS patients in the Japanese Phase III study."

1556521519_intensive-care.jpg
The Faron drug did not reduce mortality or increase the number of ventilator-free survival days

Faron Pharmaceuticals Ltd (LON:FARN) said a separate Japanese study effectively confirmed the results of an earlier phase III trial of its Traumakine drug for people with acute respiratory distress syndrome (ARDS).

In other words, it did not reduce mortality or increase the number of ventilator-free survival days when compared to placebo.

But as chief executive, Dr Markku Jalkanen, pointed out: “It appears likely that corticosteroid use diminished the treatment benefit of Traumakine in ARDS patients in the Japanese Phase III study.

“Unfortunately, the use of steroids has become a standard in ARDS despite any evidence base and this requires critical reassessment, as the use of steroids appears to worsen outcomes in certain ARDS subgroups."

Quick facts: Faron Pharmaceuticals Ltd

Price: 129 GBX

AIM:FARN
Market: AIM
Market Cap: £50.77 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Faron Pharmaceuticals Ltd named herein, including the promotion by the Company of Faron Pharmaceuticals Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

A 'thrilling' year ahead for Faron Pharmaceuticals with Phase III Traumakine...

Markku Jalkanen, chief executive at Faron Pharmaceuticals Oy (LON:FARN), caught up with Proactive following their £15mln funding aimed at accelerating the development of its two lead products. Jalkanen says the funds will allow them to prepare the way to market for Traumakine, a treatment...

on 21/2/18

RNS

Second Price Monitoring Extn

1 week, 3 days ago

Price Monitoring Extension

1 week, 3 days ago

Matins Trial Update

1 week, 6 days ago

Notice of EGM

2 weeks, 4 days ago

Holdings in Company

3 weeks, 6 days ago

Interim results

4 weeks, 1 day ago

2 min read